Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Action: Physiological Effects

Activities of Polymyxin B and Cecropin A-Melittin Peptide CA(1-8)M(1-18) against a Multiresistant Strain of Acinetobacter baumannii

José María Saugar, Teresa Alarcón, Susana López-Hernández, Manuel López-Brea, David Andreu, Luis Rivas
José María Saugar
1Centro de Investigaciones Biológicas (CSIC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Alarcón
2Servicio de Microbiología, Hospital Universitario de la Princesa, E-28006 Madrid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susana López-Hernández
2Servicio de Microbiología, Hospital Universitario de la Princesa, E-28006 Madrid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel López-Brea
2Servicio de Microbiología, Hospital Universitario de la Princesa, E-28006 Madrid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Andreu
3Department of Organic Chemistry, Universitat de Barcelona, E-08028 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Rivas
1Centro de Investigaciones Biológicas (CSIC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: luis_rivas@cib.csic.es
DOI: 10.1128/AAC.46.3.875-878.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Polymyxin B (PXB) and the cecropin A-melittin hybrid CA(1-8)M(1-18) (KWKLFKKIGIGAVLKVLTTGLPALIS-NH2) were compared for antibiotic activity on reference and multiresistant Acinetobacter baumannii strains. Significant differences for both peptides were observed on their inner membrane interaction and inhibition by environmental factors, supporting the use of CA(1-8)M(1-18) as a potential alternative to PXB against Acinetobacter.

Fatty acid-acylated polymyxins are among the most active antibiotics against gram-negative bacteria (5). Although not completely unveiled, the mechanism of action of these cyclic cationic peptides is based on self-promoted uptake through interaction with lipopolysaccharide (LPS), disorganization of the outer membrane, and further binding to the inner membrane, whose permeation is not required. (4).

Polymyxin B (PXB) was the only drug universally active against nosocomial multiresistant strains from the opportunistic pathogen Acinetobacter baumannii (2). A recent description of a PXB-resistant isolate raised clinical concern (C. Urban, N. Mariano, J. J. Rahal, E. Tay, C. Ponio, T. Koprivnjak, and J. Weiss, Letter, Antimicrob. Agents Chemother. 45:994-995, 2001). Nevertheless, this strain was susceptible to peptides such as cecropin P1 and rBPI21, supporting eukaryotic antibiotic peptides as alternative drugs for use against Acinetobacter. In tune with this, we have compared the antibiotic activity of PXB with that of the cecropin A-melittin hybrid CA(1-8)M(1-18) (KWKLFKKIGIGAVLKVLTTGLPALIS-NH2), for which strong bactericidal (17) and antiendotoxic activities (8), but no animal cytotoxicity (6, 8), have been reported. CA(1-8)M(1-18) is active against other members of the family Enterobacteriaceae in vitro (8, 9, 19) and has been tested successfully on a set of A. baumannii nosocomial isolates with different antibiotic resistance patterns (1).

Because it had a broad multiresistance pattern, the nosocomial Acinetobacter baumannii isolate Ac157 was chosen from a panel of 17 nosocomial isolates from the Microbiology Department (Hospital de la Princesa, Madrid, Spain) and tested against ticarcillin, cefotaxime, imipenem, tobramycin, amikacin, ofloxacin, and doxycycline (1). This strain was resistant to the complete panel, except for showing intermediate resistance to tobramycin as defined in reference 12. CA(1-8)M(1-18) was synthesized by solid-phase methods (3), purified by reverse-phase chromatography, and satisfactorily characterized by high-performance liquid chromatography, amino acid analysis, and matrix-assisted laser desorption ionization-time of flight mass spectrometry. Reagents were purchased from Sigma (St. Louis, Mo.), and fluorescence dyes were obtained from Molecular Probes (Leiden, Holland).

MICs were assayed at 5 × 105 CFU/ml on Mueller-Hinton (MH) broth at 37°C on polypropylene microwell plates by twofold serial dilution of the peptides (8.0 to 0.012 μM). MICs for the reference strain were 2.0 and 1.0 μM for CA(1-8)M(1-18) and PXB, respectively, whereas those for Ac157 were 2.0 to 4.0 and 1.0 to 2.0 μM. These MICs were in the same range as those determined with the previously assayed (1) panel of A. baumannii nosocomial multiresistant (to one to six drugs) strains. All strains were susceptible to colistin and to CA(1-8)M(1-18)—in this case, with MICs between 2 and 4 μM— except for one strain for which the MIC was 8 μM (1). No correlation was found among MICs and the class or number of drugs to which they were resistant (1), in agreement with the results obtained for the same peptide on other bacterial species with multiresistance to standard antibiotics. Unless otherwise stated, only data for strain Ac157 are shown, because differences from the reference strain were not significant (P > 0.1).

Determinations of parameters involving peptide-pathogen interaction were made at 107 CFU/ml, the same used for the membrane perturbation assays. Bacteria were resuspended in Hanks medium plus 20 mM glucose (Hanks+Glc) and incubated with the peptide alone or with the corresponding reagent for 30 min at 37°C. Afterwards 10-μl aliquots were transferred into a 96-well microplate containing 100 μl of MH broth, and MICs were determined by the checkerboard method by twofold dilution. At this concentration, killing curves showed a fast killing kinetics, with a reduction of 4 log orders for CA(1-8)M(1-18) and PXB after 5 or 15 min, respectively.

Although CA(1-8)M(1-18) and PXB showed identical increases in their MICs in the presence of divalent cations (or, conversely, enhanced activity in the presence of EDTA), PXB was more susceptible to changes in salinity (Table 1). In contrast, the activity of CA(1-8)M(1-18) was much more susceptible than that of PXB to inhibition by polyanions. A possible explanation is that a flexible, linear peptide such as CA(1-8)M(1-18) has a broader repertoire of potential polyanion-binding conformations than the more rigid PXB. Interestingly, CA(1-8)M(1-18) retains more activity than PXB on depolarized and/or metabolically quiescent Acinetobacter cells, like those in the stationary phase or biofilms (6).

Outer membrane sensitization to detergents (16) by both peptides was demonstrated by the fact that all MICs were decreased to 0.25 μM in the presence of 0.05% Triton X-100. Interaction with LPS was confirmed by peptide displacement of dansyl polymyxin (DPXB) bound to purified A. baumannii LPS (18) or to isolated cells (10, 14). The 50% maximal displacements (I50) of DPXB by CA(1-8)M(1-18) were 1.6 and 4.1 μM on LPS and bacterial cells, respectively, and 1.3 and 5.5 μM for PXB. The values are in the same range as those reported for Pseudomonas aeruginosa (13).

Furthermore, permeation of inner membrane was compared by two complementary approaches: (i) membrane depolarization, monitored by the increase in fluorescence of Disc3(5) (3, 3-dipropylthiadicarbocyanine iodide) (19), and (ii) influx of the membrane-impermeable probe SYTOX into the cytoplasm. Both assays were performed at 107 CFU/ml with a Hitachi F2000 spectrofluorometer. EDTA (10 mM) was included to allow Disc3(5) free access to the inner membrane. CA(1-18)M(1-18) caused a higher and faster permeabilization than PXB in both systems (Fig. 1 and 2), with a good correlation with bacterial killing, as reported for Escherichia coli (19). This was not the case for PXB, which permeabilized the membrane only at concentrations higher than the MIC (4). This fact reflects divergences in the respective lethal mechanisms, although both peptides share a self-promoted uptake when crossing the outer membrane (10, 13).

Unexpectedly, PXB at sublethal concentrations inhibited the oxygen consumption rate (measured in a Clark electrode) of Acinetobacter (108 CFU/ml in Hanks+Glc) (Table 2), as expected for an inner membrane permeabilization process. A similar inhibition of respiration of Enterobacteriaceae by immobilized PXB has been described, suggesting that a mechanism other than pure membrane permeabilization is involved (9).

Only CA(1-8)M(1-18) produced a concentration-dependent increase in DPH (1,6-diphenyl-1,3,5-hexatriene) fluorescence anisotropy (0.7 μM; 107 CFU/ml in Hanks+Glc, 37°C), measured with a Fluorolog-3 spectrofluorometer (Longjumeau, France) (11) (Fig. 3). This parameter is inversely related to membrane fluidity, evidencing interaction of CA(1-8)M(1-18), but not PXB, with the hydrophobic core of the membrane, in agreement with the small increase in surface pressure of phospholipid monolayers after PXB penetration (20).

Thus, CA(1-8)M(1-18) constitutes a good alternative to PXB against Acinetobacter, because it is active on depolarized bacteria and lacks cytotoxicity on animal models (14). Furthermore, its microbicidal activity is faster than that of PXB. Although both peptides share self-promoted uptake, this does not imply parallel mechanisms of resistance. This agrees with such findings as the PXB resistance of certain E. coli and A. baumannii strains being overcome by cecropin B (15) and cecropin P1 (Urban et al., Letter), respectively, and supports a possible use of CA(1-8)M(1-18) and other membrane-active antibiotic peptides as alternatives to the predictable appearance of PXB resistance. On the downside, further research is required to unravel the systemic pharmacology of these peptides. This may in turn result in unexpected rewards. For instance, combination therapy based on synergy among CA(1-8)M(1-18) and antibiotic peptides with nonoverlapping targets, such as buforin II (7), is an unexplored possibility that deserves further attention.

FIG. 1.
  • Open in new tab
  • Download powerpoint
FIG. 1.

Depolarization of the inner membrane of A. baumannii strain Ac157 as assessed by Disc3(5) fluorescence (λex = 622, λem = 670 nm) in the presence of CA(1-8)M(1-18) (solid symbols) or PXB (open symbols). Peptide concentrations: control, circles; 0.05 μM, hexagons; 0.5 μM, squares; 1.0 μM, diamonds; 2.0 μM, triangles. Data are representative of three independent experiments. a.u., arbitrary units.

FIG. 2.
  • Open in new tab
  • Download powerpoint
FIG. 2.

Inner membrane permeabilization in A. baumannii strain Ac157 by CA(1-8)M(1-18) and PXB measured by the increase in SYTOX green fluorescence (λex = 485, λem = 520 nm). (A) CA(1-8)M(1-18). (B) PXB. Peptide concentrations: control, circles; 0.2 μM, downward triangles; 0.5 μM, squares; 1.0 μM, diamonds; 2.0 μM, upward triangles; 5.0 μM, hexagons. Arrows indicate addition of 0.5% Triton X-100. Data are representative of three independent experiments.

FIG. 3.
  • Open in new tab
  • Download powerpoint
FIG. 3.

Effect of CA(1-8)M(1-18) and PXB on DPH anisotropy (λex =360, λem = 430 nm) on A. baumannii in the absence (solid bars) or presence (open bars) of 10 mM EDTA. Anisotropies at different temperatures (T) in the absence of peptide are included as internal controls in the inset. Data are representative of three independent experiments.

View this table:
  • View inline
  • View popup
TABLE 1.

MICs of CA(1-8)M(1-18) and PXB for A. baumannii at 107 CFU/ml under different experimental conditions

View this table:
  • View inline
  • View popup
TABLE 2.

Inhibition of oxygen consumption of A. baumannii at 4 × 108 CFU/ml by CA(1-8)M(1-18) and PXB

ACKNOWLEDGMENTS

This work was supported by grants from CAM (08/0029/1998) and FIS (99/0025) to M.L.B. and L.R., CAM Programa de Grupos Estratégicos to L.R., and CERBA, Generalitat de Catalunya to D.A. T.A. is recipient of a CAM postdoctoral fellowship.

FOOTNOTES

    • Received 3 August 2001.
    • Returned for modification 21 September 2001.
    • Accepted 21 November 2001.
  • Copyright © 2002 American Society for Microbiology

REFERENCES

  1. 1.↵
    Alarcón, T., S. López-Hernández, D. Andreu, J. M. Saugar, L. Rivas, and M. López-Brea. 2001. In vitro activity of CA(1-8)M(1-18), a synthetic cecropin A-melittin hybrid peptide, against multiresistant Acinetobacter baumannii strains. Rev. Esp. Quimioter.14:184-190.
    OpenUrlPubMed
  2. 2.↵
    Bergogne-Bérézin, E. 1996. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev.9:148-165.
    OpenUrlFREE Full Text
  3. 3.↵
    Boman, H. G., D. Wade, I. A. Boman, B. Wählin, and R. B. Merrifield. 1989. Antibacterial and antimalarial properties of peptides that are cecropin-melittin hybrids. FEBS Lett.259:103-106.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Daugelavičius, R., E. Bakienče, and D. H. Bamford. 2000. Stages of polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob. Agents Chemother.44:2969-2978.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Evans, M. E., D. J. Feola, and R. P. Rapp. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother.33:960-967.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Friedrich, C., M. G. Scott, N. Karunaratne, H. Yan, and R. E. Hancock. 1999. Salt-resistant alpha-helical cationic antimicrobial peptides. Antimicrob. Agents Chemother.43:1542-1548.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Giacometti, A., O. Cirioni, M. S. Del Prete, F. Barchiesi, A. M. Paggi, E. Petrelli, and G. Scalise. 2000. Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J. Antimicrob. Chemother.46:807-810.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    Gough, M., R. E. W. Hancock, and N. M. Kelly. 1996. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun.64:4922-4927.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    LaPorte, D. C., K. S. Rosenthal, and D. R. Storm. 1977. Inhibition of Escherichia coli growth and respiration by polymyxin B covalently attached to agarose beads. Biochemistry16:1642-1648.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Moore, R. A., N. C. Bates, and R. E. W. Hancock. 1986. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob. Agents Chemother.29:496-500.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    Müller, S., S. Ullrich, A. Lösche, N. Loffhagen, and W. Babel. 2000. Flow cytometric techniques to characterise physiological states of Acinetobacter calcoaceticus. J. Microbiol. Methods40:67-77.
    OpenUrlCrossRefPubMed
  12. 12.↵
    National Committee for Clinical Laboratory Standards. 2000. Approved standard M7-A5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
  13. 13.↵
    Piers, K. L., and R. E. Hancock. 1994. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Mol. Microbiol.12:951-958.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Piers, K. L., M. H. Brown, and R. E. W. Hancock. 1994. Improvement of outer membrane-permeabilizing lipopolysaccharide-binding activities of an antimicrobial cationic peptide by C-terminal modification. Antimicrob. Agents Chemother.38:2311-2316.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Vaara, M., and T. Vaara. 1994. Ability of cecropin B to penetrate the enterobacterial outer membrane. Antimicrob. Agents Chemother.38:2498-2501.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Viljanen, P., P. Koski, and M. Vaara. 1988. Effect of small cationic leukocyte peptides (defensins) on the permeability barrier of the outer membrane. Infect. Immun.56:2324-2329.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Wade, D., A. Boman, B. Wahlin, C. M. Drain, D. Andreu, H. G. Boman, and R. B. Merrifield. 1990. All-D amino acid-containing channel-forming antibiotic peptides. Proc. Natl. Acad. Sci. USA87:4761-4765.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Westphal, O., and K. Jann. 1965. Bacterial polysaccharides. Extraction with phenol-water and further application of the procedure, p. 83-91. In R. L. Whistler and J. N. Bemiller (ed.), Methods in carbohydrate chemistry,vol. 5. Academic Press, New York, N.Y.
    OpenUrl
  19. 19.↵
    Wu, M., E. Maier, R. Benz, and R. E. Hancock. 1999. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry38:7235-7242.
    OpenUrlCrossRefPubMed
  20. 20.↵
    Zhang, L., A. Rozek, and R. E. Hancock. 2001. Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem.276:35714-35722.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Activities of Polymyxin B and Cecropin A-Melittin Peptide CA(1-8)M(1-18) against a Multiresistant Strain of Acinetobacter baumannii
José María Saugar, Teresa Alarcón, Susana López-Hernández, Manuel López-Brea, David Andreu, Luis Rivas
Antimicrobial Agents and Chemotherapy Mar 2002, 46 (3) 875-878; DOI: 10.1128/AAC.46.3.875-878.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activities of Polymyxin B and Cecropin A-Melittin Peptide CA(1-8)M(1-18) against a Multiresistant Strain of Acinetobacter baumannii
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Activities of Polymyxin B and Cecropin A-Melittin Peptide CA(1-8)M(1-18) against a Multiresistant Strain of Acinetobacter baumannii
José María Saugar, Teresa Alarcón, Susana López-Hernández, Manuel López-Brea, David Andreu, Luis Rivas
Antimicrobial Agents and Chemotherapy Mar 2002, 46 (3) 875-878; DOI: 10.1128/AAC.46.3.875-878.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acinetobacter
Anti-Bacterial Agents
Antimicrobial Cationic Peptides
Melitten
polymyxin B

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596